CCCC earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -3.14. Updated 2026-07-23.
C4 Therapeutics (CCCC) Research Hub
C4 Therapeutics (CCCC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.98 USD (-2.61%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.14, market cap 0.31B. This hub links to the full technical, earnings and options research available for CCCC.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.98 USD (-2.61%) |
| 52-week range | 2.595 USD – 5.17 USD |
| Trend regime | Range |
| 14-day RSI | 52.9 (Neutral) |
| Trailing P/E | -3.14 |
| Market cap | 0.31B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CCCC
Covered Call on CCCC: how it works, illustrative setup around the real 2.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CCCC: how it works, illustrative setup around the real 2.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CCCC: how it works, illustrative setup around the real 2.98 USD price, max profit/loss, breakeven and when to use it. Educational.
CCCC technical analysis: range, last 2.98 USD, RSI 52.9, 52w range 2.595 USD–5.17 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CCCC in?
C4 Therapeutics (CCCC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CCCC in an uptrend or downtrend?
As of 2026-10-26, CCCC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CCCC's trailing P/E ratio?
CCCC's trailing P/E is -3.14, with a market cap of 0.31B. See the earnings research page for full valuation detail.
When does CCCC next report earnings?
CCCC is next scheduled to report earnings on 2026-08-06.